Key terms

About LIVN

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest LIVN news

Apr 02 6:55am ET Piper Sandler Keeps Their Buy Rating on LivaNova (LIVN) Mar 21 5:21am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE) Mar 20 2:38pm ET LivaNova jumps nearly 12% after saying trial likely to meet primary endpoint Mar 20 11:55am ET LivaNova’s aura6000 Poised for Success in OSA Market: A Buy Rating Overview Mar 20 9:08am ET LivaNova reports positive predictive outcome for OSPREY trial for OSA Mar 11 5:25pm ET LivaNova management to meet with Jefferies Mar 11 4:55am ET LivaNova management to meet with Jefferies Mar 10 10:25pm ET LivaNova management to meet with Jefferies Mar 06 6:12am ET LivaNova Prices $300M Convertible Notes, Secures Capped Calls Mar 04 5:33pm ET LivaNova PLC Announces $300M Convertible Notes Offering Mar 04 4:45pm ET LivaNova announces proposed offering of $300M of convertible senior notes Feb 27 5:40am ET LivaNova price target raised to $61 from $57 at Barclays Feb 26 6:16am ET LivaNova: Balancing Act Between Operational Strengths and Market Realignment Justifies Hold Rating Feb 26 6:08am ET LivaNova price target raised to $61 from $57 at Barclays Feb 22 6:49am ET LivaNova price target raised to $62 from $56 at Baird Feb 22 6:42am ET LivaNova price target raised to $75 from $70 at Mizuho Feb 21 11:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Feb 21 6:03am ET LivaNova sees FY24 adjusted EPS $2.95-$3.05, consensus $3.02 Feb 21 6:01am ET LivaNova reports Q4 adjusted EPS 87c, consensus 77c Feb 20 9:58am ET Apple, Tesla downgraded: Wall Street’s top analyst calls Feb 20 7:26am ET LivaNova upgraded to Buy from Neutral at Mizuho Feb 06 4:20am ET LivaNova Announces New CEO Appointment and Director Feb 06 4:19am ET LivaNova Announces Vladimir Makatsaria as New CEO Feb 05 10:00am ET Baird sees new CEO announcement as second positive update for LivaNova Feb 05 8:29am ET LivaNova names Vladimir Makatsaria CEO

No recent press releases are available for LIVN

LIVN Financials

1-year income & revenue

Key terms

LIVN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

LIVN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms